CVS Health Co. (NYSE:CVS) Shares Sold by Trexquant Investment LP

Trexquant Investment LP lowered its holdings in CVS Health Co. (NYSE:CVS) by 7.5% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 234,625 shares of the pharmacy operator’s stock after selling 19,159 shares during the period. Trexquant Investment LP’s holdings in CVS Health were worth $10,532,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in CVS. TD Private Client Wealth LLC increased its position in shares of CVS Health by 28.7% during the third quarter. TD Private Client Wealth LLC now owns 46,938 shares of the pharmacy operator’s stock worth $2,951,000 after acquiring an additional 10,465 shares during the period. Principal Financial Group Inc. increased its holdings in CVS Health by 4.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator’s stock worth $90,200,000 after purchasing an additional 66,244 shares during the period. Hall Laurie J Trustee raised its position in CVS Health by 25,484.4% in the 4th quarter. Hall Laurie J Trustee now owns 11,513 shares of the pharmacy operator’s stock valued at $517,000 after purchasing an additional 11,468 shares in the last quarter. B&D White Capital Company LLC acquired a new position in shares of CVS Health during the fourth quarter worth about $417,000. Finally, Watts Gwilliam & Co. LLC increased its stake in shares of CVS Health by 9.8% during the fourth quarter. Watts Gwilliam & Co. LLC now owns 7,302 shares of the pharmacy operator’s stock worth $334,000 after buying an additional 650 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at CVS Health

In other news, Director Michael F. Mahoney purchased 30,000 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the purchase, the director now directly owns 39,356 shares of the company’s stock, valued at $2,625,045.20. This represents a 320.65 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP James David Clark sold 7,513 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares in the company, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.24% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CVS. Wells Fargo & Company lifted their price target on shares of CVS Health from $68.00 to $73.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Piper Sandler boosted their target price on shares of CVS Health from $72.00 to $74.00 and gave the stock an “overweight” rating in a research note on Friday, March 21st. Evercore ISI raised their price target on CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a research note on Monday, January 27th. Wolfe Research boosted their price objective on shares of CVS Health from 67.00 to 70.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Finally, Barclays lifted their price target on shares of CVS Health from $71.00 to $73.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $70.39.

CVS Health Price Performance

Shares of CVS opened at $68.14 on Thursday. The firm has a market capitalization of $85.91 billion, a PE ratio of 18.62, a P/E/G ratio of 0.98 and a beta of 0.54. The stock’s 50 day moving average is $63.02 and its two-hundred day moving average is $57.91. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $75.27. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Research analysts anticipate that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd will be given a dividend of $0.665 per share. The ex-dividend date of this dividend is Tuesday, April 22nd. This represents a $2.66 annualized dividend and a yield of 3.90%. CVS Health’s payout ratio is currently 72.68%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.